Ali A. Solmaz

Adana, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer.

Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer.

Journal: Scientific reports

Published: April 03, 2026

Prognostic value of inflammatory-nutritional indexes and HALP score in advanced stage NSCLC treated with first-line TKI.

Prognostic value of inflammatory-nutritional indexes and HALP score in advanced stage NSCLC treated with first-line TKI.

Journal: Biomarkers in medicine

Published: September 13, 2025

Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.

Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.

Journal: International journal of cancer

Published: August 13, 2025

Prognostic Value of Metabolic Tumor Volume and Heterogeneity Index in Diffuse Large B-Cell Lymphoma.

Prognostic Value of Metabolic Tumor Volume and Heterogeneity Index in Diffuse Large B-Cell Lymphoma.

Journal: Medicina (Kaunas, Lithuania)

Published: June 19, 2025

The prognostic value of halp score in predicting the efficacy of nivolumab treatment in metastatic malignant melanoma patients: A real-life, retrospective, single center analysis.

The prognostic value of halp score in predicting the efficacy of nivolumab treatment in metastatic malignant melanoma patients: A real-life, retrospective, single center analysis.

Journal: Medicine

Published: May 05, 2025

Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study.

Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study.

Journal: Discover oncology

Published: April 30, 2025

The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.

The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.

Journal: BMC cancer

Published: December 04, 2024

Importance of 18F-fluorodeoxyglucose positron emission tomography/computed tomography heterogeneity indices in non-small cell lung cancer.

Importance of 18F-fluorodeoxyglucose positron emission tomography/computed tomography heterogeneity indices in non-small cell lung cancer.

Journal: Revista da Associacao Medica Brasileira (1992)

Published: November 17, 2024

HALP Score in Predicting Response to Treatment in Patients with Early-Stage Gastric Cancer: A Multi-Centred Retrospective Cohort Study.

HALP Score in Predicting Response to Treatment in Patients with Early-Stage Gastric Cancer: A Multi-Centred Retrospective Cohort Study.

Journal: Medicina (Kaunas, Lithuania)

Published: November 08, 2024

Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer.

Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer.

Journal: Scientific reports

Published: July 25, 2024

Don't neglect the rare adverse event with intravenous immunoglobulin: Hemolytic anemia.

Don't neglect the rare adverse event with intravenous immunoglobulin: Hemolytic anemia.

Journal: Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine

Published: February 21, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026